United Cannabis: Near-Term Clinical Trials Could Catalyze the Stock
By: Ryan Allway | CannabisFN.com
The cannabis industry has experienced tremendous growth over the past several years – especially when it comes to the potential therapeutic value. According to Google Scholar, more than 1,000 papers have been published this year alone with more than 139,000 papers in total. This research has focused on tetrahydrocannabinol (THC), cannabidiol (CBD), and various other components of the cannabis and hemp plants.
In this article, we will look at United Cannabis Corporation’s (OTCQB: CNAB) progress in initiating clinical trials to study its proprietary compounds and what that means for investors.
Prana Bio Medicinals
United Cannabis Corp.’s Prana Bio Medicinal products provide patients with a way to mix and match cannabinoids for their therapeutic purposes. Using a patent-pending technology, the company infuses cannabinoids, terpenes, and flavonoids without the use of any heat, solvents, or chemicals to produce 100% natural products. These products interact with the human endocannabinoid system, which has receptors throughout the body and is responsible for homeostasis (the maintenance of a stable internal environment). They are broken down into five color-coded categories and are available as capsules, sublinguals or topicals.
“We pride ourselves on not using any chemical solvents (i.e. nButane, C02, Ethanol, Hexane) in our extraction process,” states United Cannabis CTO Tony Verzura. “We utilize our patent-pending infusion process that extracts phytocannabinoids, terpenes, and flavonoids from raw flower material without the use of any heat. Heat ‘activates’ compounds and creates the hypnotic and euphoric feeling generally experienced with THC when paired with certain terpene profiles.
Continue reading at Cannabisfn.com
Don’t forget to like WeedTV @yourweedtv